Mevalonate Kinase Deficiency: Diagnostic and Management Challenges

Author(s):  
Puneet Kumar Choudhary ◽  
Vivek Parihar ◽  
Jagatshreya Satapathy ◽  
Narendra Kumar Bagri
2006 ◽  
Vol 27 (8) ◽  
pp. 796-802 ◽  
Author(s):  
Saskia H.L. Mandey ◽  
Marit S. Schneiders ◽  
Janet Koster ◽  
Hans R. Waterham

1997 ◽  
Vol 20 (3) ◽  
pp. 391-394 ◽  
Author(s):  
K. M. Gibson ◽  
G. F. Hoffmann ◽  
L. Sweetman ◽  
B. Buckingham

2012 ◽  
Vol 18 (35) ◽  
pp. 5746-5752 ◽  
Author(s):  
Annalisa Marcuzzi ◽  
Sergio Crovella ◽  
Lorenzo Monasta ◽  
Liza Vecchi Brumatti ◽  
Marco Gattorno ◽  
...  

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Tiziana Coppola ◽  
Bradford Becken ◽  
Heather Van Mater ◽  
Marie Theresa McDonald ◽  
Gabriela Maradiaga Panayotti

2016 ◽  
Vol 94 (10) ◽  
pp. 994-999 ◽  
Author(s):  
Julie Jurczyluk ◽  
Marcia A Munoz ◽  
Oliver P Skinner ◽  
Ryan C Chai ◽  
Naveid Ali ◽  
...  

2016 ◽  
Vol Volume 9 ◽  
pp. 101-110 ◽  
Author(s):  
Grant Schulert ◽  
Leslie Favier

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Nadia K. Rafiq ◽  
Helen Lachmann ◽  
Frodi Joensen ◽  
Troels Herlin ◽  
Paul A. Brogan

Mevalonate kinase deficiency (MKD) is a severe autoinflammatory disease caused by recessive mutations in MVK resulting in reduced function of the enzyme mevalonate kinase, involved in the cholesterol/isoprenoid pathway. MKD presents with periodic episodes of severe systemic inflammation, poor quality of life, and life-threatening sequelae if inadequately treated. We report the case of a 12-year-old girl with MKD and severe autoinflammation that was resistant to IL-1 and TNF-αblockade. In view of this, she commenced intravenous tocilizumab (8 mg/kg every 2 weeks), a humanised monoclonal antibody targeting the IL-6 receptor (IL-6R) that binds to membrane and soluble IL-6R, inhibiting IL-6-mediated signaling. She reported immediate cessation of fever and marked improvement in her energy levels following the first infusion; after the fifth dose, she was in complete clinical and serological remission, now sustained for 24 months. This is one of the first reported cases of a child with MKD treated successfully with tocilizumab and adds to the very limited experience of this treatment for MKD. IL-6 blockade could therefore be an important addition to the armamentarium for the treatment of this rare monogenic autoinflammatory disease.


2009 ◽  
Vol 20 (3) ◽  
pp. 101-107 ◽  
Author(s):  
Sylvain Normand ◽  
Benoit Massonnet ◽  
Adriana Delwail ◽  
Laure Favot ◽  
Laurence Cuisset ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document